Owkin, the first end-to-end AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has announced its expansion into the DACH region (Germany, Austria, and Switzerland). This follows partnerships with nine top centers in the region, including Charité – Universitätsmedizin Berlin, Centre Hospitalier Universitaire Vaudois (CHUV), Universitätsspital Basel, Technische Universität München (TUM), Uniklinikum Erlangen, Universitätsklinikum Leipzig, Inselspital Bern, Universitätsklinik Mannheim-Heidelberg, and Medizinische Universität Wien. These collaborations represent 24% of all outpatient cases and 15% of the total patients in the DACH region, marking significant representation of patient populations.
Guillaume Bézie, Director of Partnerships Western Europe, stated: “The Western Europe network covering France, Benelux, and DACH represents the largest pool of centers for Owkin. Partnering with top academic institutions is a crucial asset for our expansion strategy, and we are delighted to showcase our ability to significantly increase our footprint in the DACH region. By capturing the diverse landscape of human health, we empower our AI to better address the unique needs of all individuals. With our partners, we are fully committed to accelerating the secondary use of multimodal patient data to provide the right treatment for each patient.”
By analyzing vast datasets and identifying complex patterns across the nine hospitals, Owkin will utilize its AI engines and diagnostic tools to improve patient outcomes in Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), and Cardiovascular Disease (CVD). This will enable researchers to discover novel biomarkers, predict treatment responses, and develop more effective therapies tailored to individual patients.
- BiomarkerPlus (Outcome prediction): Owkin will work with Inselspital Bern, Technische Universität München (TUM), and Universitätsspital Basel to analyze multimodal patient data to identify early-stage prostate cancer patients who are most likely to fail primary curative treatment and progress to more severe disease, anticipating if they may benefit from different management strategies. Owkin is also partnering with Uniklinikum Erlangen (UKER) on MIBC to analyze H&E slides to detect FGFR3 mutations.
- TargetMatch (Target discovery): In partnership with Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität and Medizinische Universität Wien, Owkin will access a high-quality multimodal dataset, including digitized histology and RNA-seq, to better understand responses to treatment for neoadjuvant chemotherapy and identify new targets and treatment strategies in MIBC.
- TrialPlus (Clinical trial optimization): Owkin’s partnership with Universitätsklinikum Leipzig aims to use machine learning techniques to enhance clinical trial design for CVD.
- AI Diagnostics (MSIntuit® CRC): To further improve Owkin’s first CE-IVD-approved MSI pre-screening tool, MSIntuit® CRC, Owkin will collaborate with Uniklinikum Erlangen (UKER) to validate the upgraded MSIntuit CRC V2 on more diverse cohorts.
In addition to advancing research towards more personalized treatment strategies for patients with prostate cancer, MIBC, and CVD, Owkin has also expanded its MOSAIC network.
